3.4 Discussion of Qualitative Findings
Most professionals agreed that AI makes responses much faster and more accurate, especially in circumstances with a lot of alerts. However, a lack of faith in AI judgments and the fact that they can't be explained were two of the main reasons people didn't want to use them. These worries are in line with research by Gadepalli et al. (2020), which stresses the importance of explainable AI (XAI) in applications that are important for security.
Participants also stressed the importance of a hybrid strategy, in which AI handles triage and automates low-risk occurrences while humans handle complex or unclear instances. People often talked about integration problems, especially with old systems and data silos, as problems that organizations face.
4. Conclusion
In conclusion, the study showed that AI-powered solutions make cyber incident response more faster and more accurate by cutting down on the time it takes to find and respond to threats and making threat classification more accurate. Still, trust in AI judgments, lack of explainability, and trouble integrating AI into existing systems are still major obstacles to adoption, even though these operational benefits exist. Experts pointed out that a collaborative approach is needed, where AI helps human analysts instead of replacing them. To fully exploit the potential of AI in automating cyber event response while keeping trust and security in the company, we need to use explainable AI models and strategic implementation frameworks to deal with these problems.
References
1. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. Molecules, 26(19), 5905.
2. Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6).
3. Jeong, W. Y., Kwon, M., Choi, H. E., & Kim, K. S. (2021). Recent advances in transdermal drug delivery systems: A review.Biomaterials Research, 25, 1-15.
4. Jhaveri, J., Raichura, Z., Khan, T., Momin, M., & Omri, A. (2021). Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics. Molecules, 26(2), 272.
5. Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022). Recent progress in nanostructured smart drug delivery systems for cancer therapy: A review. ACS Applied Bio Materials, 5(3), 971-1012.
6. Kumar, V., Praveen, N., Kewlani, P., Arvind, Singh, A., Gautam, A. K., & Mahalingam Rajamanickam, V. (2023). Transdermal drug delivery systems. inAdvanced Drug Delivery: Methods and Applications, pp. 333-362. Singapore: Springer Nature.
7. Liu, B., & Chen, K. (2024). Advances in hydrogel-based drug delivery systems. Gels, 10(4), 262.
8. Liu, P., Chen, G., & Zhang, J. (2022). A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules, 27(4), 1372.
9. Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., ... & Gao, H. (2023). Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment.Chinese Chemical Letters, 34(2), 107518.
10. Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond.Journal of Controlled Release, 342, 53-65.
11. Pillai, A., Bhande, D., & Pardhi, V. (2023). Controlled drug delivery system. inAdvanced Drug Delivery: Methods and Applications,pp. 267-289. Singapore: Springer Nature.
12. Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., ... & Shen, Z. (2022). Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. Journal of Hematology & Oncology, 15(1), 132.
13. Wang, J., Li, B., Qiu, L., Qiao, X., & Yang, H. (2022). Dendrimer-based drug delivery systems: History, challenges, and latest developments.Journal of Biological Engineering, 16(1), 18.
14. Yan, S., Na, J., Liu, X., & Wu, P. (2024). Different targeting ligands-mediated drug delivery systems for tumor therapy. Pharmaceutics,16(2), 248.